--- title: "Niagen Bioscience (NAGE) news: class action, offering and buyback" url: "https://aibio.space/companies/niagen-bioscience/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NAGE class action, offering and buyback news: Niagen Bioscience details consumer class actions, Thorne suit and Elysium fee appeal. Niagen Bioscience, Inc." --- NAGE Niagen Bioscience, Inc. NASDAQ · United States # Niagen Bioscience (NAGE) news NAGE class action, offering and buyback news Legal · 2026-08-04 ## [Niagen Bioscience details consumer class actions, Thorne suit and Elysium fee appeal](https://aibio.space/news/niagen-bioscience-details-consumer-class-actions-thorne-suit-elysium/) Niagen and its ChromaDex subsidiary are sued in two consumer class actions and a Thorne patent case. A Federal Circuit ruling on a $9.2 million fee award to Elysium is pending. ## Latest Niagen Bioscience news 1. 2026-07-10 Financings [Niagen Bioscience sets up $50,000,000 share sales program](https://aibio.space/news/niagen-bioscience-sets-up-50-000-000-share-sales-program/) Canaccord Genuity and Roth Capital Partners are the sales agents under a June 26, 2026 agreement, for a 3% commission. The supplement puts net tangible book value at $0.97 a share against a $3.37 reference price. 2. 2026-03-19 Financings [Niagen Bioscience raises share buyback authorization to $20 million](https://aibio.space/news/niagen-bioscience-raises-share-buyback-authorization-20-million/) The board lifted the program from $10 million. The company had repurchased approximately $2.6 million of stock through March 17, 2026. 3. 2024-11-21 Financings [ChromaDex (now Niagen Bioscience) adds Roth Capital to at-the-market program](https://aibio.space/news/chromadex-now-niagen-bioscience-adds-roth-capital-market-program/) B. Riley Securities is removed from the program. Raymond James and Roth Capital Partners will continue as the sales agents. ## Niagen Bioscience at a glance - **Ticker**: NAGE - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $66.7 million ### Related companies - [GOLDENWELL BIOTECH INC.](https://aibio.space/companies/goldenwell-biotech/) OTC: GWLL - [Avenir Wellness Solutions](https://aibio.space/companies/avenir-wellness-solutions/) OTC: AVRW - [Aspire-Lakewood Holdings](https://aibio.space/companies/aspire-lakewood/) NASDAQ: ASBP - [America Great Health](https://aibio.space/companies/america-great-health/) OTC: AAGH - [Herborium Group](https://aibio.space/companies/herborium/) OTC: HBRM - [Applied Biosciences](https://aibio.space/companies/applied-biosciences/) OTC: APPB - [ProText Mobility](https://aibio.space/companies/protext-mobility/) OTC: TXTM - [VOLITIONRX LTD](https://aibio.space/companies/volitionrx/) NYSE: VNRX ### Also on NASDAQ - [Century Therapeutics](https://aibio.space/companies/century-therapeutics/) IPSC - [Jupiter Neurosciences](https://aibio.space/companies/jupiter-neurosciences/) JUNS - [Phathom Pharmaceuticals](https://aibio.space/companies/phathom-pharmaceuticals/) PHAT - [Virax Biolabs Group](https://aibio.space/companies/virax-biolabs/) VRAX - [Nkarta](https://aibio.space/companies/nkarta/) NKTX - [Zymeworks](https://aibio.space/companies/zymeworks/) ZYME ## What Niagen Bioscience does Niagen Bioscience, formerly ChromaDex, describes itself as a global bioscience company dedicated to promoting healthy aging. Its research centers on nicotinamide adenine dinucleotide (NAD+), a coenzyme that regulates cellular metabolism. The company commercializes Niagen, a proprietary form of nicotinamide riboside chloride, which it introduced as a food-grade dietary and food ingredient in 2013. In 2017 it launched Tru Niagen, a finished dietary supplement sold directly to consumers. In 2024 it launched Niagen Plus products featuring pharmaceutical-grade Niagen, which it supplies to U.S. FDA-registered 503B outsourcing facilities and to compound pharmacies abroad that prepare Niagen intravenous and injectable formulations for use with a prescription. The text says food-grade Niagen is authorized for human consumption as a dietary supplement and is generally recognized as safe, and that more than 525 published human clinical studies relate to NAD+. The company changed its name to Niagen Bioscience, and its Nasdaq ticker to NAGE, effective March 19, 2025. | Product or program | What it is | Stage | |---|---|---| | Niagen | Food-grade nicotinamide riboside ingredient for dietary and food use | | | Tru Niagen | Finished dietary supplement sold directly to consumers | | | Niagen Plus | Products featuring pharmaceutical-grade Niagen | | Summarised from the company's [10-K filed Mar 4, 2026](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/cdxc-20251231.htm). ## Niagen Bioscience annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$129.4 million](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/) | [$99.6 million](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/) | | Research and development | [$6.3 million](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/) | [$6.0 million](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/) | | Net income (loss) | [$17.4 million](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/) | [$8.6 million](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/) | | Cash from operations | [$13.5 million](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/) | [$12.1 million](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/) | | Cash and equivalents | [$64.8 million](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000043/) | [$44.5 million](https://www.sec.gov/Archives/edgar/data/1386570/000162828025009774/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $66.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Niagen Bioscience Is there a class action against Niagen Bioscience? Our latest story on this, dated Aug 4, 2026: "Niagen Bioscience details consumer class actions, Thorne suit and Elysium fee appeal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/niagen-bioscience-details-consumer-class-actions-thorne-suit-elysium/). Has Niagen Bioscience raised money recently? Our latest story on this, dated Nov 21, 2024: "ChromaDex (now Niagen Bioscience) adds Roth Capital to at-the-market program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/chromadex-now-niagen-bioscience-adds-roth-capital-market-program/). Does Niagen Bioscience have a share buyback? Our latest story on this, dated Mar 19, 2026: "Niagen Bioscience raises share buyback authorization to $20 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/niagen-bioscience-raises-share-buyback-authorization-20-million/). What is the ticker symbol of Niagen Bioscience? Niagen Bioscience, Inc. trades under the ticker NAGE on NASDAQ. Where is Niagen Bioscience listed? Niagen Bioscience, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:OCD1; LS:A2AG5N; LSX:A2AG5N. What is the SEC CIK of Niagen Bioscience? The SEC Central Index Key (CIK) for Niagen Bioscience, Inc. is 1386570. Its filings are on SEC EDGAR. How many shares does Niagen Bioscience have outstanding? 79,126,002 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-04. Which country or territory is Niagen Bioscience listed under? Our directory records Niagen Bioscience, Inc. under United States. What does Niagen Bioscience do? Our directory classifies Niagen Bioscience, Inc. as: Mixed biopharma / other operations. This is a directory classification, not a description of the pipeline. What is the ISIN of Niagen Bioscience? The ISIN recorded for Niagen Bioscience, Inc. is US1710774076. Does aibio.space cover Niagen Bioscience? aibio.space lists Niagen Bioscience, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Niagen Bioscience incorporated? SEC records list its state or country of incorporation as DE. What does Niagen Bioscience develop? Niagen Bioscience, formerly ChromaDex, describes itself as a global bioscience company dedicated to promoting healthy aging. Its research centers on nicotinamide adenine dinucleotide (NAD+), a coenzyme that regulates cellular metabolism. What is Niagen from Niagen Bioscience? Niagen: Food-grade nicotinamide riboside ingredient for dietary and food use What is Tru Niagen from Niagen Bioscience? Tru Niagen: Finished dietary supplement sold directly to consumers ## Investor discussion: Niagen Bioscience Members talk about Niagen Bioscience (NAGE). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Niagen Bioscience, newest first. Each line links the filing it comes from. 1. 2026-08-04 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000043/cdcx-20260630.htm) 2. 2026-07-10 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1386570/000121390026077234/ea0297322-424b5_niagen.htm) 3. 2026-03-19 Financings Announced a share repurchase program. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000017/ex991-nagepressreleasexsha.htm) 4. 2025-11-06 Financings Announced a share repurchase program. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1386570/000138657025000025/ex991-nagepressreleasexsha.htm) 5. 2024-12-16 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01). [Source](https://www.sec.gov/Archives/edgar/data/1386570/000162828024051374/cdxc-20241213.htm) 6. 2024-11-21 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1386570/000162828024048830/cdxc-20241120.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NAGE on TradingView](https://www.tradingview.com/symbols/NASDAQ-NAGE/). ## SEC filings and registration - **SEC name**: Niagen Bioscience, Inc. - **CIK**: 1386570 - **Industry (SIC)**: Medicinal Chemicals & Botanical Products (2833) - **US tickers**: NAGE (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 10900 WILSHIRE BLVD, LOS ANGELES, CA, 90024 - **Phone**: 310-388-6706 - **Shares outstanding**: 79,126,002 as of 2026-07-30 (10-Q filed 2026-08-04) - **Former names**: ChromaDex Corp.; CODY RESOURCES, INC. ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000043/cdcx-20260630.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000042/cdxc-20260804.htm) filed 2026-08-04 - [424B5](https://www.sec.gov/Archives/edgar/data/1386570/000121390026077234/ea0297322-424b5_niagen.htm) filed 2026-07-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000035/cdxc-20260624.htm) filed 2026-06-29 - [S-3](https://www.sec.gov/Archives/edgar/data/1386570/000121390026072796/ea0294797-s3_niagen.htm) filed 2026-06-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000031/cdxc-20260506.htm) filed 2026-05-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000030/cdcx-20260331.htm) filed 2026-05-06 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1386570/000138657026000022/cdxc-20260429.htm) filed 2026-04-29 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001386570), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Niagen Bioscience, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NAGE, recorded under United States. The directory classifies it as Mixed biopharma / other operations. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Niagen Bioscience, Inc. - **Ticker**: NAGE - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Mixed biopharma / other operations - **ISIN**: US1710774076 - **Other listed symbols**: GETTEX:OCD1; LS:A2AG5N; LSX:A2AG5N - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NAGE/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/niagen-bioscience/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Niagen Bioscience (NAGE) news: class action, offering and buyback", 2026-10-31, https://aibio.space/companies/niagen-bioscience/